複雑性尿路感染症に対するAztreonamの臨床的検討

Abstract

Aztreonamを複雑性尿路感染症に使用した.投与対象は1984年7月より1985年1月までの間に練馬総合病院泌尿器科, 立川共済病院泌尿器科に入院した複雑性尿路感染症15例である.Aztreonamは1回2 g 1日2回を静注または点滴静注で5日間連続投与した.U.T.I.薬効評価基準(第2版)に適合する11例の総合臨床効果は著効6例, 有効2例, 無効3例で有効例は全例単独感染, 無効例は全例混合感染症例であった.細菌学的効果ではグラム陰性菌はすべて除菌され, グラム陽性菌では8株中4株が除菌された.副作用は全例に認められず, 臨床的検査値にも著変は認められなかった

Efficacy and safety of Aztreonam, a monobactam antibiotic developed by E.R. Squibb & Sons, Inc. U.S.A., in complicated urinary tract infections (UTI) were studied. Aztreonam was administered to 15 patients with complicated UTI admitted to our Hospitals between July, 1984 and January, 1985. A two-gram dose of Aztreonam was administered twice a day intravenously or intraductally for 5 days consecutively. There were 11 evaluable cases in accordance with the UTI Drug Efficacy Evaluation Standard (the second issue). Overall clinical effect of these cases were "excellent" in 6 cases, "good" in 2 cases and "poor" in 3 cases. All the effective cases ("excellent" and "good") were of single infections and all the non-effective cases ("poor") were of complicated infections. All of the gram-negative pathogens and 4 of the 8 gram-positive pathogens were eliminated. In no cases were side effects or significantly abnormal laboratory findings reported. Therefore, Aztreonam is very effective and safe for complicated UTI, especially gram-negative infections.